Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-Cell Lymphoma
Shots:
- The P-III (HLX01-NHL03) clinical trial evaluates the bioequivalent safety & efficacy of HLX01 vs Rituxna (rituximab) in patients with diffuse large B-cell lymphoma (DLBCL). The 1EPs of the study include OS & PFS
- As of the cut-off date (Apr 28, 2022) from the R-CHOP & H-CHOP evaluation, of 316 evaluable patients, 6 planned treatment cycles were completed by 91.8% vs 87.3%. Moreover, the 5yrs. OS rates were 75.4% & 81% & PFS were 75.6% vs 79.6%
- Results for patients with an IPI score of 1 were significantly better than those with a score of 2 (OS: 79.4% vs 76% & PFS: 79% vs 70.4%). Additionally, Rituximab is a mAb indicated for the treatment of DLBCL & other aggressive cancers
Ref: Center for Biosimilars | Image: Shanghai Henlius Biotech
Related News:- Shanghai Henlius Biotech Reports the First Patient Dosing of HLX15 (biosimilar, daratumumab) in P-I Clinical Trial for Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
